Dynavax Reports Second Quarter 2011 Financial Results

(firmenpresse) - BERKELEY, CA -- (Marketwire) -- 07/20/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2011. Cash, cash equivalents and marketable securities were $61.7 million at June 30, 2011, compared to $53.2 million at March 31, 2011 and $72.2 million at December 31, 2010. During the second quarter, the Company raised approximately $18.7 million through its At-the-Market common stock purchase agreement with Aspire Capital and received a $6 million milestone payment from GlaxoSmithKline from the initiation of a Phase 1 trial in the partnered lupus program.



Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. The Company's lead product candidate is HEPLISAV™, a Phase 3 investigational adult hepatitis B vaccine designed to provide rapid and superior protection with fewer doses than current licensed vaccines. For more information visit .

- tables to follow -







Jennifer Lew
Vice President, Finance
510-665-7217


Michael Ostrach
Vice President and Chief Business Officer
510-665-7257

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKET WIRE
Datum: 20.07.2011 - 11:30 Uhr
Sprache: Deutsch
News-ID 36139
Anzahl Zeichen: 0

contact information:
Town:

BERKELEY, CA

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 236 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Dynavax Reports Second Quarter 2011 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von

Dynavax Technologies (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Dynavax Presents Clinical Data From Lead Cancer Immunotherapy Candidate, SD-101, ...

BERKELEY, CA -- (Marketwired) -- 12/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced clinical data from an ongoing Phase 1/2 clinical trial evaluating intratumoral administration of SD-101 in the treatment of low-grade lympho ...

Dynavax Announces Presentation of Clinical Data at ASH Annual Meeting ...

BERKELEY, CA -- (Marketwired) -- 11/30/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data at the 57th American Society of Hematology (ASH) Annual Meeting this weekend in Orlando, Florida. The det ...

Dynavax Reports Third Quarter 2015 Financial Results ...

BERKELEY, CA -- (Marketwired) -- 11/05/15 -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2015.The Company had $220.7 million in cash, cash equivalents and marketable secu ...

Alle Meldungen von Dynavax Technologies